Associated Papers
DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer.
Tan S et al.
Cancer, 2025
39876053 (PubMed )
Supplement: supplement_1.pdf
Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study.
Aoyagi Y et al.
Plos One, 2022
35358259 (PubMed )
Supplement: pone.0266112.s001.xlsx › Patients
Effectiveness of Trastuzumab Combined With Capecitabine Treatment in a Patient With Hilar Cholangiocarcinoma Complicated by Liver Metastases With an ERBB2-Activating Mutation: A Case Report.
Zeng D et al.
Frontiers in Oncology, 2022
Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
Sabatier R et al.
Frontiers in Oncology, 2022
35965534 (PubMed )
Supplement: Table_5.xlsx › mut_WES_Ovac
Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
Yang Q et al.
Neoplasia (new York, N.y.), 2020
Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma.
Bouska A et al.
Leukemia, 2017
27389057 (PubMed )
Supplement: NIHMS790817-supplement-6.xlsx › Sheet1
Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.
Arildsen NS et al.
Frontiers in Oncology, 2017
Genomic landscape of salivary gland tumors.
Kato S et al.
Oncotarget, 2015
26247885 (PubMed )
Supplement: oncotarget-06-25631-s002.xlsx › Sheet1
Select a paper to view details